Personalized Medicine in Benign and Malignant Adrenal Tumors

Dear Colleagues,

The widespread application of high-resolution cross-sectional scanning in modern medicine has led to the frequent discovery of clinically silent adrenal tumors, called “adrenal incidentalomas”. They are becoming increasingly common and have attracted attention to all adrenal tumors that are no longer considered rare. The efforts of clinicians are focused on the differential diagnosis between benign and malignant adrenal masses and identification of excess in hormone secretions (mainly hypercortisolism and primary aldosteronism), which may potentially worsen comorbidities (cardiovascular, metabolic or bone complications) and increased mortality. In this context, the impact of adrenalectomy is still debated, while new medical approaches are emerging in recent years.

Although the majority of adrenal masses are benign, adrenocortical cancer (ACC) can occur, burdened by grim prognosis, strong propensity to recur after surgery, and a limited range of available therapeutic options. Therefore, great efforts are required to identify reliable prognostic factors, novel methods to secure early diagnosis, and new markers for a timely detection of tumor recurrence following adrenalectomy. Given that the available medical therapies have limited efficacy and are quite toxic, the identification of new molecular targets that can be druggable and the development of innovative therapeutic agents is a definitive priority to improve patient care. Meanwhile, studies focusing on the efficacy and safety of existing therapies, as well as on quality of life, should be promoted.

This Special Issue will focus on all of these aspects, in particular on genetic, new “omics” markers, differential diagnosis, prognostic factors, as well as therapeutic approaches and their effects. Both original research and review articles are welcome.

Prof. Dr. Massimo Terzolo
Dr. Soraya Puglisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.